Alemtuzumab in Brazilian multiple sclerosis care: major gaps in mandatory monitoring over 24 months.

Santana J L S, Nogueira M R, Cicivizzo G P, Allioni G A, Adoni T, Callegaro D, Apóstolos-Pereira S L, Silva G D